Patents by Inventor Thomas Baumert
Thomas Baumert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
H2 Blockers Targeting Liver Macrophages for the Prevention and Treatment of Liver Disease and Cancer
Publication number: 20230349922Abstract: The present invention provides Histamine Receptor 2 antagonists and pharmaceutical compositions thereof for use in the treatment or prevention of liver disease, including liver fibrosis and hepato-biliary cancers. The present invention also relates to methods for identifying candidate compounds that are useful in the treatment or prevention of liver disease, including liver fibrosis and hepato-biliary cancers.Type: ApplicationFiled: August 11, 2021Publication date: November 2, 2023Applicants: Université de Strasbourg, Institut National de la Santé et de la Recherche MédicaleInventors: Thomas Baumert, Emilie Crouchet -
Publication number: 20230313299Abstract: The present invention relates to diagnosis and/or prognosis of liver disease progression and risk of hepatocellular carcinoma and the discovery of therapeutic compounds and targets to treat liver disease and cancer.Type: ApplicationFiled: March 2, 2021Publication date: October 5, 2023Inventors: Thomas BAUMERT, Joachim LUPBERGER, Frank Sven JÜHLING, Yujin HOSHIDA
-
Publication number: 20230138047Abstract: The present invention concerns the use of anti-Claudin-1 monoclonal antibodies, and pharmaceutical compositions thereof, for the prevention and/or treatment of a fibrotic disease in a patient, in particular pulmonary fibrosis, kidney fibrosis or skin fibrosis. Methods of preventing and/or treating pulmonary fibrosis kidney fibrosis or skin fibrosis by administration of such a monoclonal antibody, or a pharmaceutical composition thereof, are also described.Type: ApplicationFiled: November 12, 2020Publication date: May 4, 2023Inventors: Thomas Baumert, Emilie CROUCHET, Roberto IACONE, Markus MEYER, Natascha ROHLEN, Antonio SAVIANO, Catherine SCHUSTER, Tamas SCHWEIGHOFFER
-
Publication number: 20220411493Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. The tight junction protein claudin-1 (CLDN1) is an essential entry factor for HCV and a promising target for therapy. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs). The inventors also demonstrate that anti-CLDN1 H3L3 cures persistent HCV infection in human-liver chimeric uPA-SCID mice in monotherapy.Type: ApplicationFiled: April 29, 2022Publication date: December 29, 2022Applicants: INSERM (Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Chu Strasbourg, Les Hôpitaux Universitaires de StrasbourgInventors: Thomas BAUMERT, Rajeevkumar Tawar
-
Patent number: 11365251Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs).Type: GrantFiled: October 27, 2020Date of Patent: June 21, 2022Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Strasbourg, Chu Strasbourg, Les Hôpitaux Universitaires de StrasbourgInventors: Thomas Baumert, Rajeevkumar Tawar
-
Publication number: 20210309964Abstract: The present invention provides a simple and robust human liver cell-based system in which persistent hepatitis C infection, persistent hepatitis B infection or ethanol exposure induces a clinical Prognostic Liver Signature (PLS) high-risk gene signature. The cellular model system for hepatocellular carcinoma (HCC)/cirrhosis development and progression may be used in the screening of compounds useful in the treatment and/or prevention of cirrhosis and/or HCC as well as in the identification biomarkers for the prediction of liver disease (especially cirrhosis) progression and HCC. The present invention also relates to specific compounds that have been identified, using such screening methods, as useful in the treatment and/or the prevention of HCC/cirrhosis.Type: ApplicationFiled: April 22, 2021Publication date: October 7, 2021Applicants: Universite de Strasbourg, Institut National de la Sante et de la Recherche Medicale, Institut Hospitalier Universitaire de Strasbourg, ICAHN School of Medicine at Mount SinaiInventors: Thomas Baumert, Yujin Hoshida
-
Patent number: 10988737Abstract: The present invention provides a simple and robust human liver cell-based system in which persistent hepatitis C infection, persistent hepatitis B infection or ethanol exposure induces a clinical Prognostic Liver Signature (PLS) high-risk gene signature. The cellular model system for hepatocellular carcinoma (HCC)/cirrhosis development and progression may be used in the screening of compounds useful in the treatment and/or prevention of cirrhosis and/or HCC as well as in the identification biomarkers for the prediction of liver disease (especially cirrhosis) progression and HCC. The present invention also relates to specific compounds that have been identified, using such screening methods, as useful in the treatment and/or the prevention of HCC/cirrhosis.Type: GrantFiled: April 28, 2016Date of Patent: April 27, 2021Assignees: Universite de Strasbourg, Institut National de la Sante et de la Recherche Medicale Institut, Hospitalier Universitaire de Strasbourg, ICAHN School of Medicine at Mount SinaiInventors: Thomas Baumert, Yujin Hoshida
-
Patent number: 10927170Abstract: Use of anti-Claudin 1 monoclonal antibodies and pharmaceutical compositions thereof, for the prevention and/or treatment of hepatocellular carcinoma in patients suffering from liver disease, in particular liver disease that is not associated with HCV infection or in patients who have been cured from HCV infection. Methods of preventing and/or treating hepatocellular carcinoma by administration of such a monoclonal antibody, or a pharmaceutical composition thereof, are also described. Experimental results with the hepatocarcinoma cell line HuH-7.5.1 are given.Type: GrantFiled: May 15, 2018Date of Patent: February 23, 2021Assignees: Universite de Strasbourg, Institut Hospitalier Universitaire de Strasbourg, Institut National de la Sante et de la Recherche MedicaleInventors: Thomas Baumert, Eric Robinet, Mirjam Zeisel
-
Publication number: 20210040204Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs).Type: ApplicationFiled: October 27, 2020Publication date: February 11, 2021Applicants: INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Strasbourg, Chu Strasbourg, Les Hôpitaux Universitaires de StrasbourgInventors: Thomas Baumert, Rajeevkumar Tawar
-
Patent number: 10851160Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. The tight junction protein claudin-1 (CLDN1) is an essential entry factor for HCV and a promising target for therapy. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs). The inventors also demonstrate that anti-CLDN1 H3L3 cures persistent HCV infection in human-liver chimeric uPA-SCID mice in monotherapy.Type: GrantFiled: March 21, 2017Date of Patent: December 1, 2020Assignees: Institut National de la Sante et de la Recherche Medicale, Universite de Strasbourg, Chu Strasbourg, les Hopitaux Universitaires de StrasbourgInventors: Thomas Baumert, Rajeevkumar Tawar
-
Patent number: 10815298Abstract: Use of anti-Claudin 1 monoclonal antibodies and pharmaceutical compositions thereof, for the prevention and/or treatment of hepatocellular carcinoma in patients suffering from liver disease, in particular liver disease that is not associated with HCV infection or in patients who have been cured from HCV infection. Methods of preventing and/or treating hepatocellular carcinoma by administration of such a monoclonal antibody, or a pharmaceutical composition thereof, are also described. Experimental results with the hepatocarcinoma cell line HuH-7.5.1 are given.Type: GrantFiled: March 18, 2016Date of Patent: October 27, 2020Assignees: Institut Hospitalier Universitaire de Strasbourg, Institut National de la Sante et de la Recherche Medicale, Universite de StrasbourgInventors: Thomas Baumert, Eric Robinet, Mirjam Zeisel
-
Publication number: 20190100586Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. The tight junction protein claudin-1 (CLDN1) is an essential entry factor for HCV and a promising target for therapy. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs). The inventors also demonstrate that anti-CLDN1 H3L3 cures persistent HCV infection in human-liver chimeric uPA-SCID mice in monotherapy.Type: ApplicationFiled: March 21, 2017Publication date: April 4, 2019Applicants: INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Strasbourg, Chu Strasbourg, Les Hôpitaux Universitaires de StrasbourgInventors: Thomas Baumert, Rajeevkumar Tawar
-
Publication number: 20180258169Abstract: Use of anti-Claudin 1 monoclonal antibodies and pharmaceutical compositions thereof, for the prevention and/or treatment of hepatocellular carcinoma in patients suffering from liver disease, in particular liver disease that is not associated with HCV infection or in patients who have been cured from HCV infection. Methods of preventing and/or treating hepatocellular carcinoma by administration of such a monoclonal antibody, or a pharmaceutical composition thereof, are also described. Experimental results with the hepatocarcinoma cell line HuH-7.5.1 are given.Type: ApplicationFiled: May 15, 2018Publication date: September 13, 2018Inventors: Thomas BAUMERT, Eric ROBINET, Mirjam ZEISEL
-
Publication number: 20180119096Abstract: The present invention provides a simple and robust human liver cell-based system in which persistent hepatitis C infection, persistent hepatitis B infection or ethanol exposure induces a clinical Prognostic Liver Signature (PLS) high-risk gene signature. The cellular model system for hepatocellular carcinoma (HCC)/cirrhosis development and progression may be used in the screening of compounds useful in the treatment and/or prevention of cirrhosis and/or HCC as well as in the identification biomarkers for the prediction of liver disease (especially cirrhosis) progression and HCC. The present invention also relates to specific compounds that have been identified, using such screening methods, as useful in the treatment and/or the prevention of HCC/cirrhosis.Type: ApplicationFiled: April 28, 2016Publication date: May 3, 2018Inventors: Thomas BAUMERT, Yujin HOSHIDA
-
Publication number: 20180057587Abstract: Use of anti-Claudin 1 monoclonal antibodies and pharmaceutical compositions thereof, for the prevention and/or treatment of hepatocellular carcinoma in patients suffering from liver disease, in particular liver disease that is not associated with HCV infection or in patients who have been cured from HCV infection. Methods of preventing and/or treating hepatocellular carcinoma by administration of such a monoclonal antibody, or a pharmaceutical composition thereof, are also described. Experimental results with the hepatocarcinoma cell line HuH-7.5.1 are given.Type: ApplicationFiled: March 18, 2016Publication date: March 1, 2018Inventors: Thomas BAUMERT, Eric ROBINET, Mirjam ZEISEL
-
Patent number: 8759010Abstract: The present invention provides several networks of cellular protein kinases as potential targets for medical intervention against hepatitis C virus (HCV) infection and HCV-related diseases and disorders in mammals, including humans. The invention relates to therapeutic protocols and pharmaceutical compositions designed to inhibit the activity of one or more of these protein kinases for the prevention and/or treatment of infections and diseases caused by HCV. The invention also relates to methods for the identification of kinase inhibitors that may be used to treat and/or prevent HCV infections and HCV-related diseases.Type: GrantFiled: September 18, 2009Date of Patent: June 24, 2014Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Thomas Baumert, Joachim Lupberger
-
Patent number: 8518408Abstract: The present invention provides monoclonal antibodies that specifically bind to the extracellular domain of human Claudin-1 on the cell surface, thereby inhibiting HCV entry into susceptible cells and preventing HCV infection of these cells; and hybridoma cell lines which produce such monoclonal antibodies. Also provided are reagents that comprise such antibodies, and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing HCV infection by administration of an inventive monoclonal antibody, or a pharmaceutical composition thereof are also described.Type: GrantFiled: September 25, 2009Date of Patent: August 27, 2013Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), University de StrasbourgInventors: Thomas Baumert, Catherine Schuster, John Thompson, Fritz Grunert
-
Publication number: 20130129676Abstract: The present invention provides combinations of antibodies for use in the treatment or the prevention of HCV infection. In particular, combinations are provided that comprise at least one anti-HCV envelope antibody and at least one anti-HCV receptor antibody, wherein the anti-HCV-envelope antibody and anti-HCV-receptor antibody act in a highly synergistic manner to inhibit HCV entry into susceptible cells. Also provided are pharmaceutical compositions and kits comprising such combinations and methods of using these compositions and kits for treating or preventing HCV infection.Type: ApplicationFiled: May 25, 2011Publication date: May 23, 2013Applicants: UNIVERSITE DE STRASBOURG, INSERM (Institut National de la Sante et de la Recherche Medicale)Inventor: Thomas Baumert
-
Publication number: 20110236347Abstract: The present invention provides monoclonal antibodies that specifically bind to the extracellular domain of human Claudin-1 on the cell surface, thereby inhibiting HCV entry into susceptible cells and preventing HCV infection of these cells; and hybridoma cell lines which produce such monoclonal antibodies. Also provided are reagents that comprise such antibodies, and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing HCV infection by administration of an inventive monoclonal antibody, or a pharmaceutical composition thereof are also described.Type: ApplicationFiled: September 25, 2009Publication date: September 29, 2011Applicants: GENOVAC, UNIVERSITE DE STRASBOURG, INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Thomas Baumert, Catherine Schuster, John Thompson, Fritz Grunert
-
Publication number: 20110229484Abstract: The present invention provides several networks of cellular protein kinases as potential targets for medical intervention against hepatitis C virus (HCV) infection and HCV-related diseases and disorders in mammals, including humans. The invention relates to therapeutic protocols and pharmaceutical compositions designed to inhibit the activity of one or more of these protein kinases for the prevention and/or treatment of infections and diseases caused by HCV. The invention also relates to methods for the identification of kinase inhibitors that may be used to treat and/or prevent HCV infections and HCV-related diseases.Type: ApplicationFiled: September 18, 2009Publication date: September 22, 2011Applicant: INSERM (Institut National de la Sant et de la Recherche Medicale)Inventors: Thomas Baumert, Joachim Lupberger